- BRCAness Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations
[作者:Tan, DSP; Rothermundt, C; Thomas, K; Bancroft, E; Eeles, R; Shanley, S; Ardern-Jones, A; Norman, A; Kaye, SB; Gore, ME,期刊:Journal of clinical oncology, 页码:5530-5536 , 文章类型: Article,,卷期:2008年26-34]
- PurposeWe evaluated the clinical impact of germ-line BRCA1/2 mutations in patients with epithelial ovarian cancer (EOC) on responses to first and subsequent lines of chemotherapy, treatment-free interval (TFI) between ea...
- Late Congestive Heart Failure After Hematopoietic Cell Transplantation
[作者:Armenian, SH; Sun, CL; Francisco, L; Steinberger, J; Kurian, S; Wong, FL; Sharp, J; Sposto, R; Forman, SJ; Bhatia, S,期刊:Journal of clinical oncology, 页码:5537-5543 , 文章类型: Article,,卷期:2008年26-34]
- PurposeTo examine the independent roles of pre-hematopoietic cell transplantation (HCT) therapeutic exposures, transplantation-related conditioning, and comorbidities (pre- and post-HCT) in the development of late conges...
- Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
[作者:Di Leo, A; Gomez, HL; Aziz, Z; Zvirbule, Z; Bines, J; Arbushites, MC; Guerrera, SF; Koehler, M; Oliva, C; Stein, SH; Williams, LS; Dering, J; Finn, RS; Press, MF,期刊:Journal of clinical oncology, 页码:5544-5552 , 文章类型: Article,,卷期:2008年26-34]
- PurposeLapatinib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER-2/ErbB2), is effective against HER-2-positive locally advanced or meta...
- Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer
[作者:Hassett, MJ; Hughes, ME; Niland, JC; Edge, SB; Theriault, RL; Wong, YN; Wilson, J; Carter, WB; Blayney, DW; Weeks, JC,期刊:Journal of clinical oncology, 页码:5553-5560 , 文章类型: Article,,卷期:2008年26-34]
- PurposeTo describe the frequency of chemotherapy use for hormone receptor (HR)-positive, lymph node (LN)-negative breast cancer from 1997 to 2004 at eight National Comprehensive Cancer Network institutions, to explore wh...
- Roles of Radiotherapy and Chemotherapy in the Development of Contralateral Breast Cancer
[作者:Hooning, MJ; Aleman, BMP; Hauptmann, M; Baaijens, MHA; Klijn, JGM; Noyon, R; Stovall, M; van Leeuwen, FE,期刊:Journal of clinical oncology, 页码:5561-5568 , 文章类型: Article,,卷期:2008年26-34]
- Purpose Few studies have examined whether modern radiotherapy and chemotherapy affect the risk of contralateral breast cancer (CBC), and results are inconclusive.Patients and MethodsWe assessed long-term risk of CBC in a...
- Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors
[作者:Jimeno, A; Li, J; Messersmith, WA; Laheru, D; Rudek, MA; Maniar, M; Hidalgo, M; Baker, SD; Donehower, RC,期刊:Journal of clinical oncology, 页码:5504-5510 , 文章类型: Article,,卷期:2008年26-34]
- PurposeWe conducted a first-in-man (to our knowledge) phase I study to determine the dose-limiting toxicities (DLTs), characterize the pharmacokinetic profile, and document any antitumor activity of ON 01910.Na, a new ch...
- Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors
[作者:Mross, K; Frost, A; Steinbild, S; Hedbom, S; Rentschler, J; Kaiser, R; Rouyrre, N; Trommeshauser, D; Hoesl, CE; Munzert, G,期刊:Journal of clinical oncology, 页码:5511-5517 , 文章类型: Article,,卷期:2008年26-34]
- PurposeBI 2536 is a novel, potent, and highly specific inhibitor of polo-like kinase 1 (Plk1), which has an essential role in the regulation of mitotic progression. The aim of this trial was to identify the maximum toler...
- Randomized Trial of Postoperative Reirradiation Combined With Chemotherapy After Salvage Surgery Compared With Salvage Surgery Alone in Head and Neck Carcinoma
[作者:Janot, F; de Raucourt, D; Benhamou, E; Ferron, C; Dolivet, G; Bensadoun, RJ; Hamoir, M; Gery, B; Julieron, M; Castaing, M; Bardet, E; Gregoire, V; Bourhis, J,期刊:Journal of clinical oncology, 页码:5518-5523 , 文章类型: Article,,卷期:2008年26-34]
- PurposeFull-dose reirradiation combined with chemotherapy has been shown to be feasible after salvage surgery with acceptable toxicity. The Groupe d'Etude des Tumeurs de la Tete et du Cou and Groupe d'Oncologie Radiother...
- Randomized, Phase II Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Soft Tissue Sarcoma
[作者:Baker, LH; Rowinsky, EK; Mendelson, D; Humerickhouse, RA; Knight, RA; Qian, J; Carr, RA; Gordon, GB; Demetri, GD,期刊:Journal of clinical oncology, 页码:5583-5588 , 文章类型: Article,,卷期:2008年26-34]
- PurposeSarcomas are among the most proangiogenic malignancies in preclinical models. Phase I study results for ABT-510, which inhibits angiogenesis via a novel thrombospondin-mimetic mechanism, suggested activity in soft...
- EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan
[作者:Takano, T; Fukui, T; Ohe, Y; Tsuta, K; Yamamoto, S; Nokihara, H; Yamamoto, N; Sekine, I; Kunitoh, H; Furuta, K; Tamura, T,期刊:Journal of clinical oncology, 页码:5589-5595 , 文章类型: Article,,卷期:2008年26-34]
- Purpose This study evaluated whether the presence of epidermal growth factor receptor (EGFR) mutations is a predictive marker for survival benefit from gefitinib and/or a prognostic marker in patients with advanced lung ...
- Circulating 25-Hydroxyvitamin D, VDR Polymorphisms, and Survival in Advanced Non-Small-Cell Lung Cancer
[作者:Heist, RS; Zhou, W; Wang, ZX; Liu, G; Neuberg, D; Su, L; Asomaning, K; Hollis, BW; Lynch, TJ; Wain, JC; Giovannucci, E; Christiani, DC,期刊:Journal of clinical oncology, 页码:5596-5602 , 文章类型: Article,,卷期:2008年26-34]
- PurposeWe showed previously that in early-stage non-small-cell lung cancer (NSCLC), serum vitamin D levels and VDR polymorphisms were associated with survival. We hypothesized that vitamin D levels and VDR polymorphisms ...
- Temsirolimus in Patients With Renal Cancer on Hemodialysis
[作者:Lunardi, G; Vannozzi, MO; Armirotti, A; Nicodemo, M; Venturini, M; Cavallini, L,期刊:Journal of clinical oncology, 页码:5652-U182 , 文章类型: Letter,,卷期:2008年26-34]
-
- Value of Positron Emission Tomography of the Para-Aortic Lymph Nodes in Cervical Carcinoma Stage IB2-IIIB
[作者:Vergote, I; Tsolakidis, D; Mortier, D; Neven, P; Amant, F; Mottaghy, F; Van Limbergen, E,期刊:Journal of clinical oncology, 页码:5654-U186 , 文章类型: Letter,,卷期:2008年26-34]
-
- Value of Positron Emission Tomography of the Para-Aortic Lymph Nodes in Cervical Carcinoma Stage IB2-IIIB Reply
[作者:Morice, P; Bentivegna, E; Uzan, C; Gouy, S; Schlumberger, M; Duvillard, P; Haie-Meder, C,期刊:Journal of clinical oncology, 页码:5655-U189 , 文章类型: Letter,,卷期:2008年26-34]
-
|